These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24495339)

  • 21. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia.
    Sacuiu S; Insel PS; Mueller S; Tosun D; Mattsson N; Jack CR; DeCarli C; Petersen R; Aisen PS; Weiner MW; Mackin RS;
    Am J Geriatr Psychiatry; 2016 Feb; 24(2):126-35. PubMed ID: 26238228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
    Schmand B; Eikelenboom P; van Gool WA;
    J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing predictors of conversion and decline in mild cognitive impairment.
    Landau SM; Harvey D; Madison CM; Reiman EM; Foster NL; Aisen PS; Petersen RC; Shaw LM; Trojanowski JQ; Jack CR; Weiner MW; Jagust WJ;
    Neurology; 2010 Jul; 75(3):230-8. PubMed ID: 20592257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
    Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
    J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions.
    Lee GJ; Lu PH; Hua X; Lee S; Wu S; Nguyen K; Teng E; Leow AD; Jack CR; Toga AW; Weiner MW; Bartzokis G; Thompson PM;
    Biol Psychiatry; 2012 May; 71(9):814-21. PubMed ID: 22322105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment.
    Pyun JM; Park YH; Lee KJ; Kim S; Saykin AJ; Nho K;
    Transl Neurodegener; 2021 Aug; 10(1):32. PubMed ID: 34465370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting Progression From Mild Cognitive Impairment to Alzheimer's Disease Using Autoregressive Modelling of Longitudinal and Multimodal Biomarkers.
    Minhas S; Khanum A; Riaz F; Khan SA; Alvi A
    IEEE J Biomed Health Inform; 2018 May; 22(3):818-825. PubMed ID: 28534796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Follow-up Study.
    Xie B; Liu Z; Jiang L; Liu W; Song M; Zhang Q; Zhang R; Cui D; Wang X; Xu S
    J Alzheimers Dis; 2017; 55(2):509-520. PubMed ID: 27662297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
    Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Machine Learning-Based Holistic Approach to Predict the Clinical Course of Patients within the Alzheimer's Disease Spectrum.
    Massetti N; Russo M; Franciotti R; Nardini D; Mandolini GM; Granzotto A; Bomba M; Delli Pizzi S; Mosca A; Scherer R; Onofrj M; Sensi SL; ;
    J Alzheimers Dis; 2022; 85(4):1639-1655. PubMed ID: 34958014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data.
    Li K; Chan W; Doody RS; Quinn J; Luo S;
    J Alzheimers Dis; 2017; 58(2):361-371. PubMed ID: 28436391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease.
    Hall A; Muñoz-Ruiz M; Mattila J; Koikkalainen J; Tsolaki M; Mecocci P; Kloszewska I; Vellas B; Lovestone S; Visser PJ; Lötjonen J; Soininen H; ; ;
    J Alzheimers Dis; 2015; 44(1):79-92. PubMed ID: 25201784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease.
    Julayanont P; Brousseau M; Chertkow H; Phillips N; Nasreddine ZS
    J Am Geriatr Soc; 2014 Apr; 62(4):679-84. PubMed ID: 24635004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.